trending Market Intelligence /marketintelligence/en/news-insights/trending/jQkiMOYMxm_OxqC_KPizzw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

RXi Pharmaceuticals to sell up to $15M of common stock to Chicago-based fund

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


RXi Pharmaceuticals to sell up to $15M of common stock to Chicago-based fund

RXi Pharmaceuticals Corp. agreed to sell up to $15 million worth of its common shares to Chicago-based investor Lincoln Park Capital Fund LLC over a 30-month period.

RXi will control the timing of any future investment under the deal, and Lincoln Park Capital will be obligated to make purchases under the agreement.

The purchase price will be based on the market price of the shares at the time of each sale to Lincoln Park Capital, and there are no upper limits to the price Lincoln Park Capital may pay for the shares.

The company will use the proceeds for working capital and general corporate purposes, including advancing its immuno-oncology pipeline, RXi said in a news release.